Faeth Therapeutics, a clinical-stage biotechnology company focused on targeting tumor metabolism, has announced positive results from a Phase 2 clinical trial evaluating sapanisertib in combination with paclitaxel for ovarian cancer treatment. The investigator-initiated DICE trial (NCT03648489), led by researchers at Imperial College London, demonstrated that sapanisertib can improve treatment outcomes when added to the standard chemotherapy agent paclitaxel.
Trial Results to be Presented at ESMO 2025
The positive Phase 2 data will be featured as a late-breaking oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. Dr. Jonathan Krell from the Ovarian Cancer Action Research Centre at Imperial College London will present the findings on Sunday, October 19, 2025, at 11:01 am CEST in the Cologne Auditorium at CityCube A during the Mini Oral session on Gynaecological cancers.
Sapanisertib and the PIKTOR Program
Sapanisertib represents a key component of Faeth's lead multi-node PIKTOR program, which is designed to disrupt the PI3K/AKT/mTOR pathway. This therapeutic approach targets metabolic vulnerabilities in cancer cells, particularly in cancers strongly associated with obesity and metabolic disorders. The company's lead clinical program combines serabelisib, sapanisertib, and dietary intervention to create a comprehensive metabolic targeting strategy.
Company's Metabolic-Focused Approach
Faeth Therapeutics distinguishes itself by integrating targeted therapies with precision nutrition interventions to exploit metabolic vulnerabilities in cancer. The company was founded by renowned researchers from prestigious institutions including Cornell, Columbia, Cambridge, Memorial Sloan Kettering, and the Crick Institute. The founding team includes notable scientists Drs. Lewis Cantley, Siddhartha Mukherjee, Karen Vousden, Greg Hannon, and Scott Lowe.
The company leverages its AI-driven MetabOS™ discovery platform to identify metabolic targets, representing an innovative approach to cancer treatment that combines traditional targeted therapy with metabolic intervention strategies. This dual approach has shown promising outcomes in cancers that have strong associations with obesity and metabolic disorders, potentially opening new therapeutic avenues for patients with these challenging malignancies.
